Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 11/20 | 0.69 |
| ▸ | JAK2 | O60674 | 3/20 | 0.69 |
| ▸ | JAK3 | P52333 | 3/20 | 0.69 |
| ▸ | IKBKB | O14920 | 2/20 | 0.69 |
| ▸ | JAK1 | P23458 | 2/20 | 0.45 |
| ▸ | TYK2 | P29597 | 2/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.45 |
| ▸ | KDM1A | O60341 | 4/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25876759 | 0.90 | ROCK2 (0.84) | ROCK2JAK2JAK3IKBKBJAK1 | |
| SCHEMBL25876023 | 0.90 | ROCK2 (0.86) | ROCK2JAK2JAK3IKBKBJAK1 | |
| SCHEMBL25876002 | 0.88 | ROCK2 (0.67) | ROCK2JAK2JAK3IKBKBJAK1 | |
| SCHEMBL25875961 | 0.83 | ROCK2 (0.54) | ROCK2JAK2JAK3IKBKBJAK1 | |
| SCHEMBL22751907 | 0.82 | ROCK2 (0.64) | ROCK2JAK2JAK3IKBKBJAK1 | |
| SCHEMBL21845815 | 0.82 | ROCK2 (1.00) | ROCK2JAK2JAK3IKBKBJAK1 | |
| SCHEMBL25875955 | 0.82 | MAOA (0.54) | ROCK2JAK2JAK3IKBKBJAK1 | |
| SCHEMBL25875953 | 0.81 | JAK2 (0.53) | ROCK2JAK2JAK3IKBKBJAK1 | |
| SCHEMBL25875930 | 0.80 | ROCK2 (0.53) | ROCK2JAK2JAK3IKBKBJAK1 | |
| SCHEMBL25875956 | 0.80 | ROCK2 (0.58) | ROCK2JAK2JAK3IKBKBJAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227430-A1 | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | ALCON INC. (CH) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227430-A1 | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | UACA, CHUK, MAP3K2 | ROCK2 209/4885JAK2 822/4885JAK3 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.